Sourav Kalra
Sourav Kalra
Research Associate, National Institute of Pharmaceutical Education and Research Mohali
No verified email
Title
Cited by
Cited by
Year
THPdb: Database of FDA-approved peptide and protein therapeutics
SS Usmani, G Bedi, JS Samuel, S Singh, S Kalra, P Kumar, AA Ahuja, ...
PloS one 12 (7), e0181748, 2017
1802017
Structural insights of cyclin dependent kinases: implications in design of selective inhibitors
S Kalra, G Joshi, A Munshi, R Kumar
European Journal of Medicinal Chemistry 142, 424-458, 2017
292017
Toward an understanding of structural insights of xanthine and aldehyde oxidases: an overview of their inhibitors and role in various diseases
R Kumar, G Joshi, H Kler, S Kalra, M Kaur, R Arya
Medicinal Research Reviews 38 (4), 1073-1125, 2018
262018
Mechanism-based inactivation of cytochromes by furan epoxide: unraveling the molecular mechanism
N Taxak, S Kalra, PV Bharatam
Inorganic Chemistry 52 (23), 13496-13508, 2013
182013
Pyrimidine containing epidermal growth factor receptor kinase inhibitors: Synthesis and biological evaluation
G Joshi, H Nayyar, S Kalra, P Sharma, A Munshi, S Singh, R Kumar
Chemical biology & drug design 90 (5), 995-1006, 2017
172017
Albumin stabilized silver nanoparticles–clotrimazole β-cyclodextrin hybrid nanocomposite for enriched anti-fungal activity in normal and drug resistant Candida cells
C Gaurav, G Nikhil, S Deepti, S Kalra, R Goutam, GK Amit
RSC advances 5 (87), 71190-71202, 2015
162015
Relay tricyclic Pd (ii)/Ag (i) catalysis: design of a four-component reaction driven by nitrene-transfer on isocyanide yields inhibitors of EGFR
DM Sawant, S Sharma, RS Pathare, G Joshi, S Kalra, S Sukanya, ...
Chemical Communications 54 (82), 11530-11533, 2018
142018
Nanotechnology for COVID-19: therapeutics and vaccine research
G Chauhan, MJ Madou, S Kalra, V Chopra, D Ghosh, SO Martinez-Chapa
ACS nano 14 (7), 7760-7782, 2020
92020
In silico binding mechanism prediction of benzimidazole based corticotropin releasing factor-1 receptor antagonists by quantitative structure activity relationship …
N Kumar, SS Mishra, CS Sharma, HP Singh, S Kalra
Journal of Biomolecular Structure and Dynamics 36 (7), 1691-1712, 2018
92018
A review on quinoline derived scaffolds as anti-hiv agents
N Chokkar, S Kalra, M Chauhan, R Kumar
Mini Reviews in Medicinal Chemistry 19 (6), 510-526, 2019
82019
Role of genomic alterations in HER2 positive breast carcinoma: focus on susceptibility and trastuzumab-therapy
H Singla, S Kalra, P Kheterpal, V Kumar, A Munshi
Current Cancer Drug Targets 17 (4), 344-356, 2017
82017
Modeling of antitubercular activity of biphenyl analogs of 2-nitroimidazo [2, 1-b][1, 3] oxazine to rationalize their activity profile
S Kalra, A Kumar, MK Gupta
Medicinal Chemistry Research 22 (7), 3444-3451, 2013
62013
E-pharmacophore guided discovery of pyrazolo [1, 5-c] quinazolines as dual inhibitors of topoisomerase-I and histone deacetylase
G Joshi, S Kalra, UP Yadav, P Sharma, PK Singh, S Amrutkar, AJ Ansari, ...
Bioorganic Chemistry 94, 103409, 2020
52020
Recent advancements in mechanistic studies and structure activity relationship of FoF1 ATP synthase inhibitor as antimicrobial agent
R Narang, R Kumar, S Kalra, SK Nayak, GL Khatik, GN Kumar, ...
European journal of medicinal chemistry 182, 111644, 2019
42019
Computational investigation of binding mechanism of substituted pyrazinones targeting corticotropin releasing factor-1 receptor deliberated for anti-depressant drug design
MS Shekhar, T Venkatachalam, CS Sharma, HP Singh, S Kalra, N Kumar
Journal of Biomolecular Structure and Dynamics, 2018
42018
Synthetic versus enzymatic pictet-spengler reaction: An overview
S Sharma, G Joshi, S Kalra, S Singh, R Kumar
Current Organic Synthesis 15 (7), 924-939, 2018
32018
Anticancer activity of dihydropyrazolo[1,5‐c]quinazolines against rat C6 glioma cells via inhibition of topoisomerase II
G Kaur, RP Cholia, G Joshi, SM Amrutkar, S Kalra, AK Mantha, ...
Archiv der Pharmazie 351 (6), 1800023, 2018
32018
Medicinal Perspective of Indole Derivatives: Recent Developments and Structure-Activity Relationship Studies.
D Kumar, S Sharma, S Kalra, G Singh, VD Monga, B Kumar
Current Drug Targets, 2020
22020
Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo [1, 5-c] quinazolines as potential EGFR inhibitors
AJ Ansari, G Joshi, UP Yadav, AK Maurya, VK Agnihotri, S Kalra, R Kumar, ...
Bioorganic chemistry 93, 103314, 2019
22019
Knoevenagel/tandem knoevenagel and michael adducts of cyclohexane-1, 3-dione and aryl aldehydes: synthesis, DFT studies, xanthine oxidase inhibitory potential, and molecular …
S Arora, G Joshi, S Kalra, AA Wani, PV Bharatam, P Kumar, R Kumar
ACS Omega 4 (3), 4604-4614, 2019
22019
The system can't perform the operation now. Try again later.
Articles 1–20